Amazon launched Foundayo, an oral GLP-1 medication, through its pharmacy service with same-day delivery options and kiosk access in select locations. The move expands availability of weight-loss and diabetes drugs beyond traditional pharmacies and telehealth platforms.
Foundayo joins a crowded market of GLP-1 alternatives. Competitors include compounded versions from companies like Ro and Calibrate, as well as branded injectables like Ozempic and Wegovy. Amazon's distribution model leverages its logistics network to undercut delivery times.
The pill formulation differs from injectable GLP-1s that dominate the market. Oral versions typically show less dramatic weight loss in clinical trials compared to injectables, though they offer convenience for patients who prefer avoiding needles.
GLP-1s work by mimicking hormones that regulate appetite and blood sugar. Side effects include nausea, vomiting, and diarrhea. Long-term safety data remains limited, particularly for people without diabetes using these drugs primarily for weight loss.
Amazon's entry reflects massive demand. The GLP-1 market reached billions in sales as patients seek alternatives to expensive brand-name injectables. Insurance coverage remains inconsistent, pushing many toward direct-pay options.
Patients should consult doctors before starting any GLP-1 medication. These drugs require medical supervision, not just convenience of access.